Education
About Us
Working with TipRanks
Follow Us
Icon plc (ICLR)
NASDAQ:ICLR
ICLR Stock Chart & Stats
$180.25
-$3.85(-1.73%)
At close: 4:00 PM EST
$180.25
-$3.85(-1.73%)
Day’s Range― - ―
52-Week Range$125.10 - $211.00
Previous CloseN/A
Volume330.38K
Average Volume (3M)758.15K
Market Cap
$13.76B
Enterprise Value$16.87B
Total Cash (Recent Filing)$468.89M
Total Debt (Recent Filing)$3.57B
Price to Earnings (P/E)24.4
Beta0.98
Next Earnings
Feb 25, 2026EPS Estimate
3.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.31
Shares Outstanding76,359,930
10 Day Avg. Volume601,406
30 Day Avg. Volume758,155
Financial Highlights & Ratios
PEG Ratio0.76
Price to Book (P/B)1.82
Price to Sales (P/S)2.09
P/FCF Ratio15.46
Enterprise Value/Market Cap1.23
Enterprise Value/Revenue2.08
Enterprise Value/Gross Profit7.75
Enterprise Value/Ebitda14.31
Forecast
1Y Price Target
$201.00Price Target Upside11.51% Upside
Rating ConsensusHold
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Bookings And Demand StabilizationA book-to-bill ratio above one combined with rising requests-for-proposals across customer sizes signals recovering demand and potential reacceleration of bookings.
Leadership TransitionAppointment of Barry Balfe from COO to CEO supports a smooth leadership transition and leverages his established relationships with large pharma to sustain client continuity.
Strategic Partnerships And ScaleGlobal scale and strategic partnerships with large pharmaceutical companies, together with growing exposure to faster-growing biopharma clients, support long-term revenue growth and operational efficiency.
Bears Say
Elevated CancellationsElevated client cancellations are reducing revenue visibility and are pressuring reported revenue as outstanding contracts are reworked or deferred.
Margin Pressure From Pass-throughs And PricingHigher pass-through costs and intensified pricing competition are squeezing gross margins and pose a notable risk to profitability even if revenue stabilizes.
Pharma R&D Rationalizations And Demand WeaknessMulti-year Pharma R&D rationalizations and reprioritization by large drugmakers have weakened biotech demand and dampened investor sentiment, constraining upside for revenue and valuation.
Icon News
ICLR FAQ
What was Icon plc’s price range in the past 12 months?
Icon plc lowest stock price was $125.10 and its highest was $211.00 in the past 12 months.
What is Icon plc’s market cap?
Icon plc’s market cap is $13.76B.
When is Icon plc’s upcoming earnings report date?
Icon plc’s upcoming earnings report date is Feb 25, 2026 which is in 24 days.
How were Icon plc’s earnings last quarter?
Icon plc released its earnings results on Oct 22, 2025. The company reported $3.31 earnings per share for the quarter, beating the consensus estimate of $3.301 by $0.009.
Is Icon plc overvalued?
According to Wall Street analysts Icon plc’s price is currently Undervalued.
Does Icon plc pay dividends?
Icon plc does not currently pay dividends.
What is Icon plc’s EPS estimate?
Icon plc’s EPS estimate is 3.31.
How many shares outstanding does Icon plc have?
Icon plc has 76,359,930 shares outstanding.
What happened to Icon plc’s price movement after its last earnings report?
Icon plc reported an EPS of $3.31 in its last earnings report, beating expectations of $3.301. Following the earnings report the stock price went down -6.542%.
Which hedge fund is a major shareholder of Icon plc?
Currently, no hedge funds are holding shares in ICLR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Icon Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$201.00 (11.51% Upside)
$201.00 (11.51% Upside)
Blogger Sentiment
Bullish
ICLR Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 216.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-10.64%
12-Months-Change
Fundamentals
Return on Equity
6.27%
Trailing 12-Months
Asset Growth
-4.09%
Trailing 12-Months
Company Description
Icon plc
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including early development, patient recruitment and retention, strategy and analytics, late phase research, data and technology solution, and consulting and analytics services. The company's clinical development services also comprise medical imaging, clinical research and laboratory services, project management, site monitoring and management services, data management, biostatistics and programming, medical writing and publishing, medical affair, endpoint adjudication/data monitoring committees, pharmacovigilance, interactive response technologies, clinical supplies management, strategic regulatory, medical communication, and consulting and advisory services. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.
ICLR Company Deck
ICLR Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a balanced view of ICON plc's performance. While there were strong business awards and strategic investments in technology, the company faced challenges with elevated cancellations and pricing pressures affecting margins. The overall outlook remains cautiously optimistic, with expectations of normalized cancellation levels and continued technological advancements.View all ICLR earnings summariesICLR Stock 12 Month Forecast
Average Price Target
$201.00
▲(11.51% Upside)
Technical Analysis
Ownership Overview
0.40% Insiders
35.30% Mutual Funds
1.22% Other Institutional Investors
61.04% Public Companies and
Individual Investors